Analyse @AlbertBourla's tweets
I’m pleased to share data from our trial indicating that our Omicron BA.4/ 5-adapted #COVID19 vaccine continues to generate a strong immune response in adults 30 days after they receive it: on.pfizer.com/3NBx2E7
Early data from our trial evaluating our Omicron BA.4/BA.5-adapted #COVID19 vaccine show increased neutralizing antibodies compared to our Original monovalent vaccine, suggesting it could potentially provide better protection against Omicron BA.4/BA.5: on.pfizer.com/3esniyR